Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product Dasynoc

Xspray Pharma has partnered with EVERSANA for the launch and commercialization of Dasynoc, its innovative cancer therapy for chronic myeloid leukemia and acute lymphatic leukemia, in the US.

EVERSANA will provide Xspray with a dedicated commercialization team with deep experience in the successful commercialization of cancer drugs, optimizing its launch budget.

The U.S. launch of the product is planned for the second half of 2023, subject to FDA approval and an ongoing litigation process. Dasynoc is bioequivalent to Sprycel® at a 30% lower dose with significantly better variability allowing for better precision and predictability of dosing and is granted ODD by FDA for the treatment of CML and ALL.